09:40 AM EST - Oncolytics Biotech Inc : Announces reporting on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advancing toward registrational studies that could redefine treatment landscapes in multiple high-need indications. Oncolytics Biotech Inc
shares N.ONCY are trading unchanged at $0.74.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7439163664161295
